Company: NDRA
Filing Date: 2025-11-26
Form Type: 424B4
Source: 0001213900-25-115097
Chunk: 5

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-26
Form: 424B4
Chunk 5
---
 Form 10-K and subsequently filed Quarterly 
 Reports on Form 10-Q, which filings are incorporated herein by reference.                   |

In some cases, you can identify
forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”,
“expects”, “plans”, “anticipates”, “believes”, “estimates”, “projects”,
“predicts”, “potential” and similar expressions intended to identify forward-looking statements. These statements
reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent
our estimates and assumptions only as of the date of the document containing the applicable statement.

You should read this prospectus
and the documents we have filed with the SEC that are incorporated by reference and any free writing prospectus that we have authorized
for use in connection with this offering completely and with the understanding that our actual future results may be materially different
from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements.

<div align='center'>iii

PROSPECTUS SUMMARY</div>

This summary highlights information contained in other parts of this prospectus and in the documents we incorporate by reference. Because it is only a summary, it does not contain all of the information that you should consider before investing in our common stock and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere or incorporated by reference in this prospectus. You should read all such documents carefully, especially the risk factors and our consolidated financial statements and the related notes included or incorporated by reference in this prospectus, before deciding to buy shares of our common stock.

Overview

We were incorporated as a
Delaware corporation in 2007. Currently, we are developing a next-generation enhanced ultrasound technology platform-Thermo-Acoustic
Enhanced Ultrasound, or TAEUS®. Our first TAEUS platform application focuses on measuring fat in the liver. Additionally, we recently
launched a digital asset treasury (“DAT”) strategy under which the principal holding in its treasury reserve on its balance
sheet will be allocated to cryptocurrency.

Digital Asset Treasury Strategy

In 2025, the Company adopted
a DAT strategy focused on cryptocurrency, and specifically a strategy of holding one to five decentralized finance digital assets, beginning
with $H